Abstract
The future role of drug eluting stent will depend on several factors. First, there is a need for a better understanding of different mechanisms favoring stent thrombosis. Consequently, the optimal antiplatelet therapy has to be defined, patient by patient, with many unclear answers, particularly regarding the duration of treatment and the strategy for patient who are candidate to any general surgery. The validation of DES use in good CABG candidates is ongoing. Lastly, the development of new generation DES is crucial with many possible ways among which biobabsorbable coating, surface treatment and combination drugs are important approaches.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
